At $21 billion and 2x market cap Gilead got a bargain for Immunomedics and Trodelvy. If you take into account better drugs like leronlimab coming to the fore then it's merely a good price. Add longhaulers and NASH to the equation with their large patient populations and you can easily see where a $100+ billion market cap comes from and an even steeper buyout price. Then comes the myriad of other indications.

ps. From a financial standpoint the longer it takes for a combo HIV BLA to occur after an EUA the better.